论文部分内容阅读
肝纤维化是肝内弥漫性纤维组织沉积,是多种慢性肝损伤的共同后果,持续发展则成为肝硬化甚至肝癌。肝星状细胞(HSC)的活化使细胞外基质(ECM)的产生与降解不平衡,是导致肝纤维化发生发展的重要环节。氧化应激反应与肝脏的纤维化密切相关,作为一种重要的机制参与到HSC的活化和ECM的沉积,因此,抗氧化剂作为一种重要的治疗肝纤维化药物成为研究热点。笔者就近几年抗氧化剂治疗肝纤维化的研究进展进行综述。
Hepatic fibrosis is a diffuse fibrous tissue deposition in the liver, which is the common consequence of many chronic liver injuries and continues to develop into cirrhosis and even liver cancer. The activation of hepatic stellate cells (HSCs) unbalances the production and degradation of extracellular matrix (ECM), which is an important link in the development of hepatic fibrosis. Oxidative stress is closely related to hepatic fibrosis, which is an important mechanism involved in the activation of HSC and the deposition of ECM. Therefore, antioxidants as an important drug for the treatment of hepatic fibrosis has become a hot research topic. In recent years, I reviewed the progress of anti-oxidant treatment of liver fibrosis.